Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2026)

Rigel Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Work In Process rose 462.69% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 462.69% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 218.92% from the prior year.
• Work In Process grew to $6.2 million in Q1 2026 per RIGL's latest filing, from $3.9 million in the prior quarter.
• Across five years, Work In Process topped out at $6.2 million in Q1 2026 and bottomed at $572000.0 in Q2 2022.
• The 5-year median for Work In Process is $2.0 million (2023), against an average of $2.8 million.
• Across the five-year window, Work In Process jumped 1541.36% in 2022 and sank 78.38% in 2025, its largest moves.
• Year by year, Work In Process stood at $2.7 million in 2022, then declined by 29.45% to $1.9 million in 2023, then tumbled by 34.65% to $1.2 million in 2024, then jumped by 218.92% to $3.9 million in 2025, then surged by 59.31% to $6.2 million in 2026.
• Per Business Quant, the three latest RIGL Work In Process figures stand at $6.2 million (Q1 2026), $3.9 million (Q4 2025), and $5.5 million (Q3 2025).